Researchers have found that MUC16(+) is an independent risk factor for poor survival in some cancer patients, and the OS of patients with MUC16(+) cholangiocarcinoma (27.4 months) is significantly lower than that of patients with MUC16(-) (56.1 months) (234). This evidence concerns the gene MUC16 and cancer.